Privacy Policy

Your Privacy

MC2 Therapeutics and EPI Health respect the privacy of visitors to their website and are committed to the protection of visitors’ personal information. This privacy statement explains data collection and use practices of the wynzora.com website.

Description of the information MC2 Therapeutics and EPI Health (the “Companies”) may collect on this website:

The Companies collect personal identifiable information (ie, information from which you can be identified, such as name, address, telephone number, or email address) only when it is asked for and/or you voluntarily submit it to us on this website. We may use the information to respond to your requests, improve our level of service and the content of our website, provide you with tips, helpful information, product news, and updates, notify you of new products and services, and for our own internal purposes.

Non-personally identifiable information

The Companies also collect information that cannot identify you. This information is collected in a cumulative form to track data such as the total number of visits to our website, the number of visitors to each page of our website, and the domain names of our visitors’ internet service providers. We use this information, which remains in cumulative and not identifiable form, to understand how our visitors use our website so that we may improve our website and the services we offer.

Use of IP Addresses

An Internet Protocol address is a set of numbers automatically assigned to your computer whenever you log on to your internet service provider or through your organization’s local area network or wide area network. Web servers automatically identify your computer by the IP address assigned to it during your session online.

The Companies or third-party companies acting on behalf of the Companies may collect IP addresses for the purposes of systems administration and to audit the use of our website.

We may use IP addresses to identify users of our website when we feel it is necessary to enforce compliance with the website’s terms of use or to protect our service, website, or other users.

Cookies

This website uses “cookies,” a small text file that is placed on your hard disk by a web page server. Cookies help provide additional functionality to the website or help us analyze usage of the website more accurately. In all cases in which cookies are used, we will not collect information that can personally identify you without your explicit permission.

You have the ability to accept or decline cookies. Most web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies, or receive a warning before a cookie is stored, if you prefer. Please refer to your internet browser’s instructions or help screen to learn more about these functions. If you choose to decline cookies, you may not be able to fully experience the interactive features of this website or any other websites that you visit.

Sharing Personally Identifiable Information with Third Parties

The Companies will not sell or rent collected personal information to any third party for any purpose. Sometimes selected third parties are used by the Companies to provide us with services in connection with our website and such parties may, from time to time, have access to your information to enable them to provide those services.

Governing Law

These terms and conditions are governed by and construed in accordance with the laws of the United States and Delaware and you irrevocably submit to the exclusive jurisdiction of the courts in that State or location.

Our Use of European Personal Information

If you are located in the European Economic Area, we only process your Personal Information when we have a valid “legal basis,” including when:

Your European Privacy Rights

International Visitors

The sites are hosted in the United States and are intended for visitors located within the United States. If you choose to use the sites from regions of the world with laws governing data collection and use that may differ from U.S. law, then please note that you are transferring your Personal Information outside of those regions to the United States for storage and processing, which does not have the same data protection laws as your jurisdiction. When we transfer your Personal Information to the United States, we take steps to comply with applicable data protection law, in particular legal requirements regarding adequate protection for data transfers. Also, we may transfer your data from the U.S. to other countries or regions in connection with storage and processing of data, fulfilling your requests, and operating the sites. By providing any information, including Personal Information, on or to the sites, you consent to such transfer, storage, and processing.

European Visitors

If you are located in the European Economic Area, we will comply with applicable EEA data protection law when transferring your Personal Information outside of the EEA. We may transfer your Personal Information to countries which have been found to provide adequate protection by the EU Commission (eg, Switzerland, Canada), use contractual protections for the transfer of Personal Information, or transfer to recipients who have certified to the Privacy Shield or adopted Binding Corporate Rules. For more information about how we transfer Personal Information outside of the EEA, or to obtain a copy of the contractual safeguards we use for such transfers, please contact us.

arrow

Indication and Use

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 2. US Department of Health and Human Services. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 41st ed. US Government Publishing Office; 2021. https://www.fda.gov/media/71474/download. Accessed April 21, 2021. 3. Wynzora® Cream [package insert]. MC2 Therapeutics; 2020. 4. MC2 Therapeutics. PAD™ Technology. https://padcream.com/. Accessed February 19, 2021.